RET inhibitor · small molecule
enbezotinib
0 active trials, targeting RET/SRC. Not approved for any biomarker on marked.bio yet.
Also known as TPX-0046.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| RET fusion or mutation | 0 | 1 | – |
Trials
0 of 1 trials shown
-
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
…gical or cytological confirmation of advanced/metastatic solid tumors harboring oncogenic RET fusions or mutations, who either have disease progression on, or are intolerant to standard thera…
RET fusion or mutationNon Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
No trials match these filters.